On 1st November 2021, representatives from across the UK cell and gene therapy community came together to discuss the UK's leadership in cell and gene therapy with the goal of leveraging experience to inform future best practice and ensure system readiness for routine ATMP clinical adoption.
On 1st November 2021, representatives from across the UK cell and gene therapy community came together to discuss the UK’s leadership in cell and gene therapy with the goal of leveraging experience to inform future best practice and ensure system readiness for routine ATMP clinical adoption. The Roundtable report summarises discussions held on the day between industry, NHS, regulators and patient groups on the past, present and future challenges in the UK ATMP ecosystem.
The Roundtable culminated in calls for a thought-leadership document to be produced that recommends that a ‘National Vision on Cell and Gene Therapies’ should be developed to set out the actions that will be taken to retain the UK’s position as a world leader on ATMPs.
Read the full roundtable report by clickinghere.